Today, Senator Josh Hawley (R-MO) introduced legislation that would rollback some of the impending cuts to federal Medicaid funding as mandated by H.R. 1.
AMCP held a Precision Medicine Partnership Forum to examine solutions to challenges of access, consistency, and quality in precision oncology.
The Department of Health and Human Services (HHS) sent out an RFI. AMCP provided a response which aims to promote precision medicine through a reconsideration of the "14 Day Rule".
Findings published in JMCP for a 3-phase AMCP Market Insights program on Food Allergies that included a national survey of managed care professionals, in-depth interviews with managed care experts, and a moderated virtual roundtable discussion including clinical and managed care experts.
On July 4, President Trump signed H.R. 1, often referred to as the One Big Beautiful Bill Act, into law.
Key insights from the discussion related to supporting patient needs in MS, advancing understanding of MS, emerging treatments in MS, using real-world evidence in MS coverage decision-making, and addressing continued challenges in MS. Suggested payer best practices in MS also emerged from the discussion.
This toolkit makes it easy to share your Unscripted—The AMCP Podcast episode, highlight your insights, and amplify your voice across your network.
On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law.
On July 3, 2025, CMS announced new opioid safety edit submission guidelines for Medicare Part D sponsors for 2026.
Medicare Part D sponsors must have concurrent drug utilization review (DUR) systems, policies, and procedures designed to ensure that a review of the prescribed drug therapy is performed before each prescription is dispensed to an enrollee in a sponsor’s Part D plan, typically at the POS or point of distribution as described in 42 CFR § 423.153(c)(2).
